Jaguar Health Files 8-K on Equity Sales

Ticker: JAGX · Form: 8-K · Filed: 2025-05-02T00:00:00.000Z

Sentiment: neutral

Topics: equity-sale, filing

TL;DR

Jaguar Health sold unregistered equity, check for dilution.

AI Summary

On April 30, 2025, Jaguar Health, Inc. filed an 8-K report detailing unregistered sales of equity securities. The filing also includes financial statements and exhibits, with the report being filed as of May 2, 2025. The company, formerly known as Jaguar Animal Health, Inc., is incorporated in Delaware and headquartered in San Francisco, California.

Why It Matters

This filing indicates potential dilution for existing shareholders due to the unregistered sale of equity securities, which could impact the stock price.

Risk Assessment

Risk Level: medium — Unregistered sales of equity can lead to dilution and signal potential financial distress or a need for capital.

Key Players & Entities

FAQ

What type of equity securities were sold?

The filing states 'Unregistered Sales of Equity Securities' but does not specify the exact type or amount in the provided text.

When was the earliest event reported in this 8-K?

The earliest event reported was on April 30, 2025.

What is Jaguar Health, Inc.'s principal executive office address?

The principal executive offices are located at 200 Pine Street Suite 400, San Francisco, California, 94104.

What was Jaguar Health, Inc. formerly known as?

The company was formerly known as Jaguar Animal Health, Inc.

What is the SIC code for Jaguar Health, Inc.?

The Standard Industrial Classification code is 2834, Pharmaceutical Preparations.

From the Filing

0001193125-25-111691.txt : 20250502 0001193125-25-111691.hdr.sgml : 20250502 20250502170042 ACCESSION NUMBER: 0001193125-25-111691 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250430 ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250502 DATE AS OF CHANGE: 20250502 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Jaguar Health, Inc. CENTRAL INDEX KEY: 0001585608 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36714 FILM NUMBER: 25909704 BUSINESS ADDRESS: STREET 1: 200 PINE STREET SUITE 400 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 415-371-8300 MAIL ADDRESS: STREET 1: 200 PINE STREET SUITE 400 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 FORMER COMPANY: FORMER CONFORMED NAME: Jaguar Animal Health, Inc. DATE OF NAME CHANGE: 20130830 8-K 1 d883453d8k.htm 8-K 8-K false 0001585608 0001585608 2025-04-30 2025-04-30     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2025     Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter)       Delaware   001-36714   46-2956775 (State or Other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.) 200 Pine Street Suite 400     San Francisco , California     94104 (Address of Principal Executive Offices)     (Zip Code) Registrant’s Telephone Number, Including Area Code:  (415)   371-8300   (Former Name or Former Address, if Changed Since Last Report)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, Par Value $0.0001 Per Share   JAGX   The Nasdaq Stock Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 3.02 Unregistered Sales of Equity Securities. On April 30, 2025, the Company entered into a privately negotiated exchange agreement (the “Exchange Agreement”) with a holder of royalty interest in the Company. Pursuant to the Exchange Agreement, the Company issued 57,500 shares of common stock to such holder in exchange for a $632,500 reduction in the outstanding balance of the royalty interest held by such holder. The shares of common stock that were issued in the exchange transaction described a

View on Read The Filing